Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy

A. Tsuji, M. Nakamura, T. Watanabe, D. Manaka, H. Matsuoka, M. Kataoka, M. Takeuchi, W. Ichikawa, M. Fujii

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)v68-v69
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Publication statusPublished - 01-06-2018

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this